Psoriatic Arthritis M15-998
Do You Have Psoriatic Arthritis?
NOW ENROLLING FOR A LOCAL INVESTIGATIONAL STUDY
A member of our staff will be in contact with you shortly.
Have you tried everything, and are still searching for a solution to psoriatic arthritis? Clinvest is investigating a new investigational drug, but we need your participation to explore new horizons in health.
We are searching for Springfield area applicants to participate in a clinical research study. The goal of this study is to assess a new investigational medication for Psoriatic Arthritis. If you’ve ever wished there was a way to stop psoriatic arthritis, then we ask for your help in researching this possibility!
WHAT SHOULD I EXPECT?
The purpose of this study is to evaluate the efficacy and safety of risankizumab 150 mg for the potential treatment of signs and symptoms of psoriatic arthritis (PsA) in subjects with moderately to severely active PsA who do not respond to treatment after at least 12 weeks of therapy or for subjects who cannot take 1 or more conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARD) or biologic therapies.
The study is up to 233 weeks, 26 visits.
TO FIND OUT MORE
LEARN MORE ABOUT OUR STUDIES
Clinvest Research is a clinical investigation company based in southwest Missouri. We are constantly seeking participants for clinical trials in order to further options for sufferers of various conditions. Our doctors are a part of a select group of clinics in the U.S. that have been involved in over 200 Phase II-IV clinical research studies sponsored primarily by the pharmaceutical industry or studies created by doctors after patient observation.
Study visits are conducted via outpatient and do not require overnight stays. In fact, we pride ourselves in making your participation in the studies as easy and convenient as possible.
If you qualify and choose to join a study, you will be treated by our team of specialists and may receive study-related care at no cost. Call us at (417) 883-7889 to learn more.